Palisade Bio presents a discussion on FSCD treatment challenges and the potential of PALI-2108 with Dr. Brian Feagan.
Quiver AI Summary
Palisade Bio, Inc. has released a Virtual Investor KOL Connect segment featuring Dr. Brian Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD). Dr. Feagan, who has extensive experience in IBD clinical research, discussed the significant unmet need for more effective treatments for FSCD, highlighting the limitations of current therapies. He introduced PALI-2108, a novel therapeutic approach designed to address inflammation while minimizing side effects. The segment offers insights into the evolving treatment landscape for IBD and the potential impact of PALI-2108. More information about the company and its advancements in therapeutic approaches can be found on their website.
Potential Positives
- Moderated discussion with Dr. Brian Feagan, a recognized expert in Fibrostenotic Crohn's Disease and Inflammatory Bowel Diseases, enhances the company's credibility and visibility in the medical community.
- Dr. Feagan highlighted the significant unmet need for effective treatments in FSCD, positioning PALI-2108 as a potential leader in addressing this market gap.
- The localized approach of PALI-2108 aims to reduce side effects while maintaining therapeutic effectiveness, which could attract interest from both patients and healthcare providers.
Potential Negatives
- The press release emphasizes the significant unmet need for more effective therapeutics in Fibrostenotic Crohn's Disease, which may suggest that existing treatments are inadequate, potentially reflecting poorly on the current market position of Palisade Bio.
- Despite the focus on PALI-2108, the need for a "novel approach" could indicate that the company's current pipelines may lack innovation or effectiveness compared to competitors.
- The mention of challenges with current approved therapies may raise concerns about the company’s ability to successfully compete and gain traction in a challenging therapeutic landscape.
FAQ
What is the focus of Palisade Bio?
Palisade Bio is focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases.
Who is Dr. Brian Feagan?
Dr. Brian Feagan is a leading expert in Fibrostenotic Crohn's Disease and IBD, and a professor at Western University.
What is PALI-2108?
PALI-2108 is a novel therapeutic being developed to address inflammation and fibrosis in inflammatory bowel diseases.
What challenges exist with current FSCD therapies?
Current therapies for Fibrostenotic Crohn's Disease often do not effectively address both inflammation and fibrotic processes.
Where can I access the virtual segment with Dr. Feagan?
The virtual segment featuring Dr. Feagan can be accessed through the Palisade Bio website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PALI Hedge Fund Activity
We have seen 5 institutional investors add shares of $PALI stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 144,764 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $98,453
- CETERA INVESTMENT ADVISERS removed 70,006 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $47,660
- UBS GROUP AG removed 37,751 shares (-99.1%) from their portfolio in Q2 2025, for an estimated $25,674
- XTX TOPCO LTD added 27,337 shares (+inf%) to their portfolio in Q2 2025, for an estimated $18,591
- HRT FINANCIAL LP removed 18,264 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,421
- VIRTU FINANCIAL LLC removed 15,255 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,374
- NEWBRIDGE FINANCIAL SERVICES GROUP, INC. added 10,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $7,141
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PALI Analyst Ratings
Wall Street analysts have issued reports on $PALI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Brookline Capital issued a "Buy" rating on 05/13/2025
To track analyst ratings and price targets for $PALI, check out Quiver Quantitative's $PALI forecast page.
Full Release
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
– Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, MD, FRCPC. Dr. Feagan is a Professor of Medicine, Epidemiology & Biostatistics at Western University, a practicing gastroenterologist at London Health Sciences Centre, and Senior Scientific Director at Alimentiv, Inc. He is a founding member of the Stenosis Therapy and Antifibrotic Research (STAR) Consortium, the founder of Robarts Clinical Trials (now Alimentiv), and globally recognized leaders in IBD clinical research. Dr. Feagan has directed more than 140 randomized controlled trials in Crohn’s disease and ulcerative colitis, developed widely used outcome measures including the Robarts Histopathology Index, and published extensively in the field. He is internationally recognized as a leading authority in FSCD and clinical trial design.
As part of the segment, Dr. Feagan discussed FSCD and the challenges with current approved therapies, highlighting the significant unmet need for more effective therapeutics that address both inflammation and the fibrotic process. He also provided his perspective on the novel approach of PALI-2108 and how it could potentially impact the overall treatment landscape. PALI-2108’s localized approach is designed to reduce class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity.
The Virtual Investor KOL Connect segment featuring Palisade Bio is now available here .
For more information about PALI-2108 and the Company’s development plans, visit www.palisadebio.com .
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com .
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]
